Trevi Therapeutics, Inc. TRVI
14.82 USD -0.10 (-0.64%)
At closeNov 12, 2026, 8:36 AM EST
14.65 -0.16 -1.11%
Pre-market · Nov 12, 8:36 AM ET
14.48 Day range 15.12
9.82 52-week range 20.22
- YTD
- +18.33%
- 1 year
- +22.44%
News
seekingalpha.com Trevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript Trevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript
marketbeat.com What Trevi Therapeutics (TRVI) Said on Its Q3 Earnings Call Trevi Therapeutics NASDAQ: TRVI said it remains on track to report results from its lead chronic cough trials in 2027 and 2028, while preparing a new study in patients with interstitial lung disease…
benzinga.com Trevi Therapeutics Q3 2026 Earnings Call Transcript Trevi Therapeutics (NASDAQ:TRVI) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Trevi Therapeutics Q3 EPS $(0.13), Inline Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 62.5 percent decrease over losses of $(0.08) per share from the…
globenewswire.com Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting Positive meeting with the FDA on the non-IPF…
benzinga.com Trevi Therapeutics Announces Results From Phase 2b CORAL Trial Accepted As Oral Presentation At CHEST 2026 Annual Meeting Of American College Of Chest Physicians Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with…
benzinga.com Trevi Therapeutics Q2 2026 Earnings Call Transcript Trevi Therapeutics (NASDAQ:TRVI) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For…
benzinga.com Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28 Jones Trading analyst Debanjana Chatterjee maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $24 to $28.- benzinga.com Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25 Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $24 to $25.
benzinga.com Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30 Cantor Fitzgerald analyst Josh Schimmer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $25 to $30.- benzinga.com Trevi Therapeutics Q2 EPS $(0.11), Inline Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 22.22 percent decrease over losses of $(0.09) per share from the…
benzinga.com This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
benzinga.com This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.
benzinga.com BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36 BMO Capital analyst Connor Murphy initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Outperform rating and announces Price Target of $36.
benzinga.com B. Riley Securities Maintains Buy on Trevi Therapeutics, Raises Price Target to $31 B. Riley Securities analyst Mayank Mamtani maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $21 to $31.
benzinga.com Global Payments To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Monday Wall Street analysts change ratings for FITB, TRVI, JAZZ, GPN, EAT, URBN, MNST. See full list on benzinga.com/analyst-stock-ratings- benzinga.com HC Wainwright & Co. Maintains Buy on Trevi Therapeutics, Raises Price Target to $24 HC Wainwright & Co. analyst Brandon Folkes maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $21 to $24.
benzinga.com ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big gainers: PHOE, SG, TRVI, DCBO, ZNTL, GPRE, SLS, FEIM, TRV, BHVN, KOS, BJRI, MBX.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals (NASDAQ:SHPH)…
benzinga.com Needham Reiterates Buy on Trevi Therapeutics, Maintains $23 Price Target Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $23 price target.- benzinga.com HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.
- benzinga.com Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $23 Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and lowers the price target from $24 to $23.
- benzinga.com Trevi Therapeutics Q1 2026 Earnings Call Transcript
- benzinga.com Trevi Therapeutics Q1 EPS $(0.09) Misses $(0.07) Estimate Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is unchanged from the same period last…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com What's Going On With Trevi Therapeutics Stock? Trevi Therapeutics shares are trading higher after it announced pricing of its $150 million offering of 11.6 million shares at $13 per share.
benzinga.com Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session US stock futures rise, Dow up by 250 pts. Netflix shares fall 9.6% after weak forecast & Reed Hastings' departure. Other stocks also dip in pre-market.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Why Blaize Holdings Shares Are Trading Higher By 24%; Here Are 20 Stocks Moving Premarket Blaize Holdings rose 24.3% in pre-market trading on $50M contract with NeoTensr & MOU with Winmate for edge AI deployments. Other gainers & losers.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Trevi Therapeutics Commences $150M Common Stock Offering Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients…
benzinga.com These Analysts Revise Their Forecasts On Trevi Therapeutics Following Q4 Earnings Trevi Therapeutics reported a smaller loss in Q4, beating analyst estimates. Share price fell 2.5%. Analysts have mixed opinions on buying TRVI stock.- benzinga.com Morgan Stanley Maintains Overweight on Trevi Therapeutics, Lowers Price Target to $18 Morgan Stanley analyst Judah Frommer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and lowers the price target from $19 to $18.
benzinga.com Nvidia To Rally Around 79%? Here Are 10 Top Analyst Forecasts For Wednesday Top analysts changed outlook on top names. Mizuho, Needham, Rothschild & Co, HC Wainwright & Co, Stifel, BTIG, Goldman Sachs made changes.
benzinga.com Needham Maintains Buy on Trevi Therapeutics, Raises Price Target to $24 Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $22 to $24.- benzinga.com Trevi Therapeutics Q4 EPS $(0.06) Beats $(0.10) Estimate Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 41.18 percent. This is a 45.45 percent increase over losses of…
- benzinga.com Earnings Scheduled For March 17, 2026
- benzinga.com HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.
- benzinga.com Trevi Therapeutics Wins FDA Support to Advance Chronic Cough Drug Into Phase 3 Trials Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients…
benzinga.com Trevi Therapeutics' Phase 2b CORAL Trial Results Published In JAMA Shows Nalbuphine ER Significantly Reduces Chronic Cough, With Over 60% Of Patients Achieving 50% Cough Reduction Statistically-significant reduction in the relative change from baseline in 24-hour objective cough frequency observed across all dose groups of nalbuphine ER at Week 6 with statistically-significant…- benzinga.com HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $21 price target.
benzinga.com Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - benzinga.com D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $19 Price Target D. Boral Capital analyst Jason Kolbert maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $19 price target.
- benzinga.com Trevi Therapeutics Intends To Start Phase 2b Study In Participants With Refractory Chronic Cough In H1 2026, Company's Chronic Cough In Idiopathic Pulmonary Fibrosis Granted End-Of-Phase 2 Meeting With FDA Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients
- benzinga.com Stifel Maintains Buy on Trevi Therapeutics, Raises Price Target to $18 Stifel analyst Annabel Samimy maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $15 to $18.
- benzinga.com Trevi Therapeutics Appoints Veteran Finance Leader David Hastings as New CFO Starting January 2026 Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients…
- benzinga.com Leerink Partners Maintains Outperform on Trevi Therapeutics, Raises Price Target to $16 Leerink Partners analyst Faisal Khurshid maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $13 to $16.
- benzinga.com Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $24 Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $23 to $24.
- benzinga.com Morgan Stanley Maintains Overweight on Trevi Therapeutics, Raises Price Target to $19 Morgan Stanley analyst Judah Frommer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $18 to $19.